Direct-Acting Oral Anticoagulant (DAOC) Score

The DOAC Score estimates bleeding risk in atrial fibrillation patients treated with direct oral anticoagulants 1.

Age, years
< 65065-69+270-74+375-79+4≥ 80+5
Creatinine clearance/estimated glomerular filtration rate (mL/min)
> 60030-60+1< 30+2
Underweight (body mass index < 18.5 kg/m2)
No0Yes+1
Stroke/transient ischemic attack/embolism history
No0Yes+1
Diabetes
No0Yes+1
Hypertension
No0Yes+1
Antiplatelet use
No0Aspirin+2Dual-antiplatelet+3
NSAID use
No0Yes+1
Bleeding history
No0Yes+3
Liver disease
No0Yes+2

Indicações de Uso

Used to estimate major bleeding risk in patients with atrial fibrillation receiving a DOAC, aiding decisions on dose selection and intensity of monitoring. Provides individualized bleeding-risk prediction with better discrimination than HAS-BLED in large external validation cohorts (AUC 0.67 vs 0.64; 21,142 patients) 1 [Level II evidence]. Developed/validated from RE‑LY, GARFIELD‑AF, COMBINE‑AF, and RAMQ cohorts with robust internal and external validation 2 [Level II evidence].

Insights e Precauções

Identifies bleeding risk in DOAC‑treated AF but offers only modest discrimination (c‑statistic ~0.73 in derivation) and may overestimate high‑risk categories 1. External validation shows AUC ~0.67 and only slight improvement over HAS‑BLED 2. Use only to flag modifiable risks, not to decide against anticoagulation, as guidelines warn scores should not guide withholding OAC 3.